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BACKGROUND: The purpose of this study was to assess the efﬁcacy and safety and to explore the dose response
of esketamine intravenous (IV) infusion in patients with treatment-resistant depression (TRD).
METHODS: This multicenter, randomized, placebo-controlled trial was conducted in 30 patients with TRD.
Patients were randomly assigned 1:1:1 to receive an IV infusion of .20 mg/kg or .40 mg/kg esketamine or placebo
over 40 minutes on day 1. The primary end point was change in Montgomery–Åsberg Depression Rating Scale
total score from day 1 (baseline) to day 2. Nonresponders who received placebo on day 1 were randomly assigned
again 1:1 to IV esketamine .20 mg/kg or .40 mg/kg on day 4. Secondary efﬁcacy and safety measures were also
evaluated.
RESULTS: Of the enrolled patients, 97% (29 of 30) completed the study. The least squares mean changes (SE) from
baseline to day 2 in Montgomery–Åsberg Depression Rating Scale total score for the esketamine .20 mg/kg and .40
mg/kg dose groups were 216.8 (3.00) and 216.9 (2.61), respectively, and showed signiﬁcant improvement (one-
sided p = .001 for both groups) compared with placebo (23.8 [2.97]). Esketamine showed a rapid (within 2 hours) and
robust antidepressant effect. Treatment-emergent adverse events were dose dependent. The most common
treatment-emergent adverse events were headache, nausea, and dissociation; the last-mentioned was transient
and did not persist beyond 4 hours from the start of the esketamine infusion.
CONCLUSIONS: A rapid onset of robust antidepressant effects was observed in patients with TRD after a 40-minute
IV infusion of either .20 mg/kg or .40 mg/kg of esketamine. The lower dose may allow for better tolerability while
maintaining efﬁcacy.
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Biohttp://dx.doi.org/10.1016/j.biopsych.2015.10.018Major depressive disorder (MDD) is a recurrent and disabling
psychiatric illness that is projected to be the leading cause of
disease burden worldwide by 2030 (1,2). Nearly one third of
patients with MDD do not achieve remission from currently
available treatments and are considered to have treatment-
resistant depression (TRD), which is associated with chron-
icity, morbidity, and functional disability (3–6). A signiﬁcant
need exists to develop novel treatments for patients with TRD
(7–9).
Ketamine is a racemate that comprises the R-(2)-ketamine
enantiomer (arketamine) and the S-(1)-ketamine enantiomer
(esketamine). Esketamine has a threefold to fourfold higher
afﬁnity for N-methyl-D-aspartate (NMDA) receptors than arke-
tamine (10–12). The mechanism of action putatively results
from noncompetitive binding to NMDA glutamate receptors.& 2016 Society of Biological Psychiatry. This is an open access a
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc
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SEE COMMENTARYThe rapid-onset antidepressant effects associated with keta-
mine and its reported efﬁcacy in patients with depression who
had been unresponsive to conventional antidepressant treat-
ments have generated considerable interest among clinicians
and researchers (13–20). In addition, most of the studies
conducted previously focused on the safety and efﬁcacy
of a single intravenous (IV) ketamine infusion (.5 mg/kg)
(14,16,19). However, there is evidence that most patients
who respond to ketamine relapse within several days or up
to 1 week after a single infusion (14,21,22). It is important to
identify a strategy for maintaining the antidepressant effects of
ketamine. This proof-of-concept trial evaluates, for the ﬁrst
time, the antidepressant efﬁcacy and safety proﬁle of .20 mg/kg
and .40 mg/kg IV esketamine compared with IV placebo in
patients with TRD.rticle under the
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PsychiatryMETHODS AND MATERIALS
The protocol and informed consent documents were approved
by independent ethics committees or institutional review
boards. Written informed consent was obtained from all
participants at screening.
Participants
Participants included men and women 18–64 years old who
met DSM-IV-TR (23) diagnostic criteria for recurrent MDD
without psychotic features, based on clinical assessment
and conﬁrmed by the Mini-International Neuropsychiatric
Interview (24). Based on the conventional deﬁnition of TRD
(25), patients were required to have had an inadequate
response to at least one antidepressant drug in their current
depressive episode and an inadequate response to at least
one other antidepressant either in their current or in a previous
depressive episode, as assessed by the Massachusetts Gen-
eral Hospital Antidepressant Treatment Response Question-
naire (4). At screening and on day 21, patients were also
required to have a total score of at least 34 on the Inventory of
Depressive Symptomatology–Clinician Rated, 30-Item (mild,
12–23; moderate, 24–36; severe, 37–46; very severe, 47–84)
(26). Exclusion criteria included any primary DSM-IV-TR
diagnosis of active generalized anxiety disorder, panic
disorder, obsessive-compulsive disorder, posttraumatic stress
disorder, anorexia nervosa, or bulimia nervosa; patients
were also excluded if they had been acutely suicidal
or homicidal requiring hospitalization in the past 12 months
or had a history of previous nonresponse to ketamine or
esketamine.
Study Design
This double-blind (DB), double-randomization, placebo-con-
trolled, multicenter study comprised three phases: screening
(up to 2 weeks), DB treatment (day 1 to day 7), and posttreat-
ment (4 weeks, comprising an optional open-label phase
lasting up to 2 weeks and a follow-up phase making up the
remainder). On day 1 (ﬁrst dose) of the DB treatment phase,
patients were randomly assigned 1:1:1 to receive an IV
infusion of .20 mg/kg or .40 mg/kg esketamine or placebo
(.9% saline solution) over 40 minutes. All patients received the
study medication by continuous infusion using an electronic
infusion pump, which was managed by an anesthesiologist or
other physician experienced with ventilation management in
each clinical site. Responders after the single dose were
deﬁned as patients experiencing a reduction of .50% in the
Montgomery–Åsberg Depression Rating Scale (MADRS) (27)
total score on days 2, 3, or 4 (before the second dose) versus
day 1 (baseline). On day 4 (second dose) of the DB treatment
phase, responders received the same treatment as day 1. For
nonresponders, the following rules were applied: 1) patients
who received placebo on day 1 were randomly assigned again
1:1 to IV esketamine .20 mg/kg or .40 mg/kg, and 2) patients
who received esketamine .20 mg/kg or .40 mg/kg on day 1
received esketamine .40 mg/kg on day 4.
For both randomizations (on day 1 and day 4), central
randomization was implemented based on a computer-
generated randomization schedule prepared by the sponsorBiological Psychibefore the study. The randomization was balanced by using
randomly permuted blocks and was stratiﬁed by study center.
On day 21 or day 1 before dosing, the unblinded pharmacist
at each study site contacted the randomization center and
provided the required subject information. The randomization
center assigned a randomization number to the subject and
informed the unblinded pharmacist at the site about the
assigned treatment. On day 3 or day 4 (before the second
dose), the investigator informed the unblinded pharmacist
whether the subject was a responder or not. To maintain
study blinding, the pharmacist contacted the randomization
center for each subject (responders and nonresponders) to
obtain a new randomization number. During the study, the
subject was assessed by qualiﬁed trained site raters who were
blinded to the subject’s treatment. After completing the DB
treatment phase, patients—with clinical input from the physi-
cian investigators—could choose to receive up to four optional
open-label treatments of IV esketamine .40 mg/kg (or lower)
on days 7, 10, 14, and 17. Per protocol, if IV esketamine was
not well tolerated on day 1 or day 4, the dose for the open-
label treatment could start at .30 mg/kg.
Outcome Measures
The primary end point was change in MADRS total score from
day 1 (baseline) to day 2 (24 hours after the ﬁrst infusion). The
typical recall period for the MADRS is 7 days, although the
MADRS was also administered for a recall period of 2 hours, 4
hours, 24 hours, and since last assessment. For the 2-hour
and 4-hour recall periods, the sleep and appetite items were
not assessed. Predose scores for these two items obtained on
the same day were carried forward unchanged.
Secondary end points included 1) change in MADRS total
score from day 1 (baseline) to day 3 and day 4 (before the
second dose) and from day 4 (before the second dose) to day
7; 2) change in MADRS total score from day 1 (baseline) to day
35 (including days 7, 10, 14, 17, 21, 28, and 35); 3) proportion
of responders after the single dose on days 2, 3, or 4
compared with placebo; 4) change in the Quick Inventory of
Depressive Symptomatology–Self Report, 16-Item score from
day 1 (baseline) to day 14; and 5) change from day 1 (baseline)
to day 7 on Clinical Global Impression–Severity, Clinical Global
Impression–Improvement, Patient Global Impression of
Severity, and Patient Global Impression of Change.
Safety assessments included treatment-emergent adverse
events (TEAEs), clinical laboratory tests, 12-lead electrocardio-
gram, vital signs, physical examinations, Columbia Suicide
Severity Rating Scale (C-SSRS), Clinician Administered Dis-
sociative States Scale (CADSS), Brief Psychiatric Rating Scale
(BPRS), and Massachusetts General Hospital-Cognitive and
Physical Functioning Questionnaire (MGH-CPFQ). All TEAEs
were followed to satisfactory resolution or to a clinically stable
end point.
Statistical Analyses
Between each esketamine group and placebo, a planned
sample size of 10 per treatment group was estimated to
provide 90% power to detect 1) a difference of 60% in
response rate (one-sided Fisher’s exact test, .10 signiﬁcance
level), assuming a 20% placebo response rate, and 2) aatry September 15, 2016; 80:424–431 www.sobp.org/journal 425
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Psychiatrydifference of 40% in MADRS total score reduction (two-
sample t test, .10 signiﬁcance level), assuming SD of 32% (16).
The intent-to-treat analysis set for all efﬁcacy analyses
included all randomly assigned patients who received at least
one dose of study medication and had baseline and at least
one postbaseline efﬁcacy assessment during the DB phase. A
mixed-effects model using repeated measures was performed
on change in MADRS total score from day 1 (baseline) to day 4
(predose). The model included baseline MADRS total score as
a covariate and day, treatment, center, and day-by-treatment
interaction as ﬁxed effects as well as a random subject effect.
An unstructured variance-covariance matrix was used. The
response rate after the single dose in each esketamine group
was compared with placebo using a logistic regression model
including baseline MADRS total score and treatment.
An analysis of variance or covariance on rank test was used
to analyze Clinical Global Impression–Improvement, Patient
Global Impression of Change, or change in Clinical Global
Impression–Severity or Patient Global Impression of Severity
score from day 1 (baseline) to days 2, 3, or 4 (predose). In
addition, summary statistics were provided by treatment
sequence for 1) change in MADRS total score from day 4
(predose) to days 5, 6, and 7; 2) change in Quick Inventory of
Depressive Symptomatology–Self Report, 16-Item score from
day 1 (baseline) to days 7 and 14; and 3) Clinical Global
Impression–Improvement, Patient Global Impression of
Change, or change in Clinical Global Impression–Severity or
Patient Global Impression of Severity score on days 5 through
7. All safety analyses were performed on the safety analysis
set, which included all randomly assigned patients who
received at least one dose of study drug. Safety results were
summarized descriptively.
RESULTS
Baseline Characteristics
Of the 42 patients screened, 30 were randomly assigned to
three treatment groups (Supplemental Figure S1). There were
29 (97%) patients who completed the DB phase and entered
the posttreatment phase; 1 patient withdrew because of a
TEAE (dissociative symptoms; detailed in Safety). Of the 29Table 1. Demographic and Baseline Characteristics
Placebo Eske
(n = 10)
Age, Years, Mean (SD) 42.7 (10.89)
Sex, F/M, n (%) 6/4 (60/40)
Race, White/Other, n (%) 10/0 (100/0)
Weight, kg, Mean (SD) 77.9 (20.51)
Body Mass Index, kg/m2, Mean (SD) 27.8 (5.23)
MADRS Total Score, Mean (SD) 33.9 (4.15)
IDS-C30 Category, Severe/Very Severe, n (%) 8/2 (80/20)
Lifetime Failed Antidepressants, n (%)
2 2 (20)
3 1 (10)
$4 7 (70)
F, female; IDS-C30, Inventory of Depressive Symptomatology–Clinician
Rating Scale.
426 Biological Psychiatry September 15, 2016; 80:424–431 www.sobppatients, 26 opted for the optional open-label treatment phase.
Three patients declined to participate in the open-label treat-
ment phase because of personal reasons that prevented them
from traveling to the clinic.
Patient demographics and baseline psychiatric characteristics
were generally balanced across treatment groups (Table 1).
The Inventory of Depressive Symptomatology–Clinician Rated,
30-Item scores were in the severe range for 80% of patients
and in the very severe range for 20% of patients. In the current
episode of depression, 67% of patients had had an inad-
equate response to at least two antidepressant treatments,
and the remaining 33% of patients had had an inadequate
response to one antidepressant treatment (and an inadequate
response to at least one other antidepressant in a previous
depressive episode). The two most common lifetime prior
failed antidepressants were venlafaxine and duloxetine, both
of which are serotonin-norepinephrine reuptake inhibitors.
Other common failed antidepressants included mirtazapine,
paroxetine, escitalopram, bupropion, and sertraline. During the
DB phase, all 30 patients received two infusions of study
medication. During the posttreatment phase, all 26 patients
who opted for open-label treatment received at least two
doses, and 21 (81%) patients received all four doses. Three
patients had dose reductions (one from .40 mg/kg to .30 mg/
kg and two from .40 mg/kg to .20 mg/kg) during this phase.
Efﬁcacy
The improvement in depressive symptoms, as measured by
reduction in MADRS total score 24 hours after treatment, was
signiﬁcantly greater in both esketamine groups compared with
the placebo group (one-sided with .10 signiﬁcance level, p =
.001 for both esketamine groups). The least squares mean
changes (SE) from day 1 (baseline) were 23.8 (2.97) for
placebo, 216.8 (3.00) for esketamine .20 mg/kg, and 216.9
(2.61) for esketamine .40 mg/kg; effect sizes (Cohen’s d) were
21.54 and 21.70 for the esketamine .20 mg/kg and .40 mg/kg
groups, respectively. As illustrated in the plot of mean MADRS
total score over time (day 1 predose until day 4 predose)
(Figure 1), esketamine showed rapid (within 2 hours) and
robust antidepressant effects at each dose tested. Consistent
with the primary efﬁcacy result, most secondary efﬁcacytamine .20 mg/kg Esketamine .40 mg/kg Total
(n = 9) (n = 11) (N = 30)
44.7 (13.38) 41.8 (11.63) 43.0 (11.59)
5/4 (56/44) 7/4 (64/36) 18/12 (60/40)
9/0 (100/0) 10/1 (91/9) 29/1 (97/3)
86.8 (25.69) 78.4 (19.37) 80.8 (21.41)
29.4 (9.94) 27.3 (4.71) 28.1 (6.65)
33.1 (3.55) 33.7 (5.82) 33.6 (4.54)
7/2 (78/22) 9/2 (82/18) 24/6 (80/20)
5 (56) 1 (9) 8 (27)
1 (11) 3 (27) 5 (17)
3 (33) 7 (64) 17 (57)
Rated, 30-Item; M, male; MADRS, Montgomery–Åsberg Depression
.org/journal
Figure 1. Mean Montgomery–Åsberg Depression Rating Scale (MADRS)
total score over time by dose. The x-axis is not proportional to real time to
accommodate up to day 35. Error bars represent SE. D, day; H, hour; PD,
predose.
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Psychiatryoutcomes after the ﬁrst DB dose showed signiﬁcant differ-
ences between the two esketamine groups and the placebo
group (Table 2).
There were no responders among placebo patients; the
proportions of patients who met responder’s criteria were 67%
and 64% for the esketamine .20 mg/kg and .40 mg/kg groups,
respectively. Nonresponders to the ﬁrst dose (day 1) of
placebo or .20 mg/kg esketamine improved after the second
dose on day 4, and the largest improvements on days 5, 6,
and 7 versus day 4 (predose) were observed in the groups that
switched from placebo to esketamine .20 mg/kg or .40 mg/kg
(Supplemental Table S1 and Supplemental Figure S2). Overall,
change in MADRS total score from day 1 to day 35 indicated
robust and persistent efﬁcacy with esketamine (Supplemental
Table S1).Safety
The overall percentage of patients with TEAEs during the
combined DB and posttreatment phases was similar in the
placebo (50%) and esketamine .20 mg/kg (50%) treatment
sessions but was higher in the esketamine .40 mg/kg (70%)
treatment session (Table 3). The three groups in Table 3 are
per actual doses in individual treatment sessions and are not
mutually exclusive, as the esketamine .40 mg/kg treatment
session included all randomly assigned patients and had
longer exposure duration to the study drug because all
patients who entered the open-label treatment phase per
protocol received the .40 mg/kg dose. The most common
(reported by $10% of patients) TEAEs were as follows:
placebo, nausea (20%), headache (20%), and tooth infection
(10%); esketamine .20 mg/kg, nausea (25%) and headache
(17%); esketamine .40 mg/kg, headache (23%), dissociation
(17%), and nausea (10%). During the esketamine-free follow-
up phase, the TEAEs reported by at least one patient were
headache (11%), nausea (7%), and constipation (7%).
Most TEAEs were mild or moderate. There were two severe
TEAEs during the DB phase and one severe TEAE during the
posttreatment phase. One of the two severe TEAEs during the
DB phase led to the discontinuation of study drug. The patient
(who had received placebo on day 1) experienced intolerableBiological Psychidissociative symptoms (reported as visual hallucinations,
depersonalization and derealization, and disturbances in log-
ical thinking) with onset during the infusion of .40 mg/kg
esketamine on day 4 that lasted for 1 hour. The infusion was
interrupted at 28 minutes, and the event resolved without any
other intervention. The CADSS score at 40 minutes after the
infusion started was 51, but it decreased to 33 at 4 hours
postinfusion. The investigator assessed the event as very likely
related to the study drug. The other severe TEAE during the
DB phase occurred 15 minutes after infusion of esketamine
.40 mg/kg on day 1. This TEAE was moderate initially but
intensiﬁed to severe dissociation at 40 minutes postinfusion
and then returned to moderate dissociation and resolved. The
CADSS score at 40 minutes postinfusion was 75, but it
decreased to 0 at 4 hours postinfusion. The one severe TEAE
during the posttreatment phase was also the only serious
adverse event of the study. This patient received six doses of
esketamine (.20 mg/kg on day 1 and .40 mg/kg on days 4, 7,
10, 14, and 17) and responded on days 10, 14, 17, 28, and 35.
At all assessment visits, the patient’s CADSS and BPRS
scores were 0, and vital signs, electrocardiograms, and clinical
laboratory assessments were within normal ranges. On day
23, the patient fell and sustained an injury to his wrist, and later
his vehicle collided with a parked car when he drove.
Examination the next day (day 24) revealed a fracture in his
right wrist, and the patient was found to have a lung tumor
with brain metastasis, which had not been known at study
entry. The investigator considered these serious adverse
events to be unrelated to study medication. The patient was
referred for treatment of lung cancer.
No deaths occurred during the study. No clinically signiﬁ-
cant changes in laboratory tests, electrocardiograms, or
physical examinations were observed. The only clinically
signiﬁcant vital sign abnormalities were a case of irregular
breathing and a case of transient high blood pressure (both
with esketamine .40 mg/kg dosing), which resolved within 2
hours without intervention. During the combined DB and
posttreatment phases, the C-SSRS results (Supplemental
Table S2) indicated that no patients had treatment-emergent
suicidal behavior or suicidal intent. The C-SSRS suicidal
ideation scores either improved or were maintained from
screening through the open-label treatment portion of the
posttreatment phase for all but one patient (received eske-
tamine .40 mg/kg on days 1, 4, 10, and 17), whose C-SSRS
scores ﬂuctuated between improvement and worsening at
various time points but ultimately approached the baseline
level at the last measurement point on day 17. The MGH-
CPFQ outcomes (Supplemental Table S3) appeared to indi-
cate that esketamine treatment was associated with improve-
ment of cognitive and physical functioning.
The mean BPRS total score reached a maximum (which
was dose related) at 30–40 minutes after the start of infusion
of .20 mg/kg or .40 mg/kg esketamine and then diminished
and approached the baseline value 2 hours after the start
of infusion (Figure 2A). The CADSS results displayed a similar
pattern as the BPRS results. The mean CADSS total score
was the highest (which was dose related) at 40 minutes
after the start of infusion of .20 mg/kg or .40 mg/kg
esketamine but returned to the baseline level 4 hours after
the start of infusion (Figure 2B). No subjects had dissociativeatry September 15, 2016; 80:424–431 www.sobp.org/journal 427
Table 2. Secondary Efﬁcacy Outcomes After First Double-
Blind Dose
Placebo
Esketamine
.20 mg/kg
Esketamine
.40 mg/kg
(n = 10) (n = 9) (n = 11)
Change in MADRS Total Score, Baseline to Day 3
LS mean change (SE) 22.3 (3.38) 216.3 (3.45) 213.4 (3.03)
p value (minus placebo)a — .003 .009
80% CIa — (219.9, 28.1) (216.7, 25.4)
Change in MADRS Total Score, Baseline to Day 4 (Predose)
LS mean change (SE) 23.1 (3.51) 214.2 (3.59) 213.2 (3.16)
p value (minus placebo)a — .014 .018
80% CIa — (217.3, 24.9) (216.0, 24.1)
Proportion of Responders to First Dose
Responder, n (%)b 0 6 (67) 7 (64)
Odds ratio (vs. placebo) — 40.2 34.5
p value (vs. placebo)c — .013 .014
Change in CGI-S Score, Baseline to Day 2
Mean change (SD) 2.2 (.42) 21.4 (1.33) 21.6 (1.21)
p value (minus placebo)d — .003 .002
Change in CGI-S Score, Baseline to Day 3
Mean change (SD) 2.2 (.63) 21.3 (1.50) 21.4 (1.36)
p value (minus placebo)d — .013 .012
Change in CGI-S Score, Baseline to Day 4 (Predose)
Mean change (SD) 2.2 (.63) 21.6 (1.42) 21.4 (1.36)
p value (minus placebo)d — .006 .007
CGI-I Score, Day 2
Mean (SD) 3.7 (.48) 2.6 (1.24) 2.5 (1.21)
p value (minus placebo)e — .009 .007
CGI-I Score, Day 3
Mean (SD) 3.9 (.74) 2.6 (1.01) 2.8 (1.25)
p value (minus placebo)e — .004 .018
CGI-I Score, Day 4 (Predose)
Mean (SD) 3.7 (.48) 2.7 (1.00) 2.8 (1.17)
p value (minus placebo)e — .007 .015
Change in PGI-S Score, Baseline to Day 2
Mean change (SD) 2.2 (.42) 2.2 (.44) 2.6 (1.12)
p value (minus placebo)d — .460 .082
Change in PGI-S Score, Baseline to Day 3
Mean change (SD) 2.2 (.42) 2.7 (.87) 2.4 (.51)
p value (minus placebo)d — .078 .088
Change in PGI-S Score, Baseline to Day 4 (Predose)
Mean change (SD) 2.3 (.48) 2.8 (.97) 2.6 (.82)
p value (minus placebo)d — .151 .132
PGI-C Score, Day 2
Mean (SD) 3.9 (.32) 3.2 (.67) 3.2 (.87)
p value (minus placebo)e — .004 .006
PGI-C Score, Day 3
Mean (SD) 3.9 (.57) 3.0 (.71) 3.6 (1.43)
p value (minus placebo)e — .013 .115
PGI-C Score, Day 4 (Predose)
Mean (SD) 3.9 (.57) 3.1 (.78) 3.3 (.91)
p value (minus placebo)e — .012 .020
CGI-I, Clinical Global Impression–Improvement; CGI-S, Clinical
Global Impression–Severity; CI, conﬁdence interval; LS, least squares;
MADRS, Montgomery–Åsberg Depression Rating Scale; PGI-C,
Patient Global Impression of Change; PGI-S, Patient Global Impres-
sion of Severity.
ap values (one-sided with level of signiﬁcance of 10%) and CIs (two-
sided) are based on the mixed-effect model using repeated measures
with baseline score as a covariate and day, treatment, center, and day-
by-treatment interaction as ﬁxed effects as well as a random patient
effect.
bResponders were deﬁned as patients who had a reduction in
MADRS total score of .50% from baseline on days 2, 3, or 4
(predose).
cp values (one-sided with level of signiﬁcance of 10%) are based
on the logistic regression model with treatment and baseline
MADRS.
dp values (one-sided with level of signiﬁcance of 10%) are based on
the analysis of covariance on rank test with original baseline score as a
covariate and with treatment and center effects.
ep values (one-sided with level of signiﬁcance of 10%) are based on
the analysis of variance on rank test with treatment and center.
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Psychiatrysymptoms that persisted beyond 4 hours after drug
administration.DISCUSSION
The primary efﬁcacy end point was reached in demonstrating
improvement in depressive symptoms, as measured by
change in MADRS total score from day 1 to day 2. The results
were statistically signiﬁcant and clinically meaningful for both
esketamine dose groups, .20 mg/kg and .40 mg/kg, versus
placebo, as demonstrated by the high effect size. No clear
dose response was observed between the two doses.
Robust onset of efﬁcacy for both esketamine dose groups
was evident 2 hours after infusion (the earliest time point
measured), as assessed by the MADRS total score. These
results stand in sharp contrast to the time course of response
typically seen with conventional oral treatments for MDD,
which are reported for efﬁcacy end points at 4–12 weeks
postdose (28). The strong efﬁcacy signal found in this trial was
also reﬂected by the responder analysis, which showed 67%
(esketamine .20 mg/kg) and 64% (esketamine .40 mg/kg) of
the patients with TRD responding, whereas no patient in this
study responded to placebo infusion. These response rates
were achieved within 3 days of a single esketamine dose. In
contrast, approved oral combinations of antipsychotics and
monoaminergic antidepressants for TRD or inadequately
responsive MDD have response rates of approximately
37%–56% after 6–12 weeks (28). Finally, response rates by
MADRS with IV esketamine in the present study appear to be
similar to the rates observed with IV ketamine in published
studies (13,16,18,21). Although differences in study design
limit direct comparisons, the results support the hypothesized
similar efﬁcacy of esketamine to racemic ketamine, based on
the higher afﬁnity of esketamine for the NMDA receptor. With
esketamine being three to four times more potent than arke-
tamine at NMDA receptors (10–12), .20 mg/kg and .40 mg/kg
esketamine correspond to a racemic ketamine dose equivalent
of approximately .31 mg/kg and .62 mg/kg (11), respectively.
Moreover, because the metabolism of esketamine tends to be
higher in the absence of arketamine (29,30), the .40 mg/kg.org/journal
Table 3. TEAEs for Combined Double-Blind and Open-Label
Phases by Dose
Patients reporting, n (%)a
Placebob
Esketamine
.20 mg/kgc
Esketamine
.40 mg/kgd
(n = 10) (n = 12) (n = 30)
Patients With at Least One
TEAE
5 (50) 6 (50) 21 (70)
Patients With Drug-Related
TEAEse
3 (30) 3 (25) 20 (67)
Patients With TEAEs Leading
to Death
0 0 0
Patients With Drug-Related
SAEs
0 0 0
Discontinuation of Study
Agent Because of TEAEsf
0 0 0
TEAEs Reported by at Least 5% of Patientsg
Dissociation 0 1 (8) 5 (17)
Dizziness 0 1 (8) 1 (3)
Dry mouth 0 1 (8) 2 (7)
Headache 2 (20) 2 (17) 7 (23)
Nasopharyngitis 0 0 2 (7)
Nausea 2 (20) 3 (25) 3 (10)
Oropharyngeal pain 0 1 (8) 1 (3)
Paresthesia 0 0 2 (7)
Rash 0 1 (8) 0
Thrombophlebitis 0 1 (8) 0
Tooth infection 1 (10) 0 0
Vertigo 0 0 2 (7)
Vomiting 0 1 (8) 1 (3)
SAE, serious adverse event; TEAE, treatment-emergent
adverse event.
aPercentages are calculated with the number of patients in each
group as denominator. Incidence is based on the number of patients
experiencing at least one adverse event, not the number of events.
bPlacebo includes 10 patients in the placebo group from day 1
(baseline) to day 4 (predose).
cEsketamine .20 mg/kg includes nine patients in the esketamine .20
mg/kg group from day 1 (baseline) to day 4 (predose) and three
nonresponders to placebo from day 1 (baseline) to day 4 (predose)
who were then randomly assigned to esketamine .20 mg/kg treatment
during the second randomization.
dEsketamine .40 mg/kg includes all randomly assigned patients.
eStudy drug relationships of “possible,” “probable,” and “very
likely” are included in this category.
fAction taken of “drug withdrawn” is included in this category but
“drug interrupted” is not.
gReported dictionary version: Medical Dictionary for Regulatory
Activities 15.1; http://www.meddra.org/how-to-use/support-documen-
tation/english.
Esketamine in Adult Treatment-Resistant Depression
Biological
Psychiatryesketamine dose was selected as comparable to .5 mg/kg
ketamine, whereas the .20 mg/kg dose was selected to test
the efﬁcacy of a lower dose. However, doses lower than those
assessed herein warrant testing to establish a minimum
effective dose.
Similar to ketamine, esketamine led to transient dissociative
and psychotic symptoms. According to CADSS severity
categories (16,31), the peak mean CADSS total scores at
40 minutes postinfusion on day 1 for the esketamine .20
mg/kg and .40 mg/kg groups would be categorized as high.Biological PsychiHowever, symptoms subsided to baseline levels within
4 hours. The CADSS scores showed evidence of dose depen-
dence on each DB dosing day. A similar pattern was observed
for psychotic-like effects measured using BPRS total scores.
These results are similar to results of IV ketamine studies
(13,14,16–18).
When used in high dosages or as a drug of abuse, ketamine
has also been associated with short-lasting, completely
reversible or long-lasting cognitive impairment. Cognitive
assessments of healthy volunteers showed that subanesthetic
infusion of ketamine leads to transient, dose-dependent
cognitive effects (32). In a 1-year study of recreational users,
infrequent ketamine use (less than four times a week but at
least once a month) of presumably high dosages was not
associated with long-term cognitive impairment, but frequent
use (more than four times a week) was associated with
impaired short-term and long-term memory (33). The patients
with TRD in the present study endorsed subjective symptoms
reﬂecting cognitive impairment at baseline (evidenced by the
mean baseline MGH-CPFQ scores), which was expected
because “diminished ability to think or concentrate, or inde-
cisiveness” is one of the core DSM-IV-TR criteria for MDD (23).
After the ﬁrst dose on day 1, an improvement in the MGH-
CPFQ score was observed in patients who were assigned to
both esketamine treatment arms. After the second dose on
day 4, the largest MGH-CPFQ improvements were observed in
patients who switched from placebo to esketamine .20 mg/kg
or .40 mg/kg, whereas patients previously treated with eske-
tamine on day 1 maintained their favorable rating. Further
studies with formal cognitive testing are needed to evaluate
the long-term risks and beneﬁts of novel treatment paradigms
targeted to the NMDA receptor.
Our study has some limitations. One design limitation was
that no CADSS assessment was obtained between the
40-minute and the 4-hour postdose time points, so we could
not establish the precise time course of either the peak
dissociative symptoms or of their resolution. Based on the ke-
tamine literature, we anticipate that these side effects would
have resolved by the 2-hour time point, but the data acquired
here do not allow that inference. Another potential limitation
was that the 0% response rate to placebo was lower than the
hypothesized 20% response rate estimated for the power
analysis. Relatively few data have been published that provide
placebo response rates after only one treatment day; most
studies instead have assessed such rates following $1 week
of placebo administration. Nevertheless, even for a TRD
sample and assessments after 1 day, the rate observed in
this study appears remarkably low. In addition, although the
modest sample size of 30 subjects is greater than that for
randomized controlled and open-label studies of racemic
ketamine (18,34), the small sample size limits the interpreta-
tions that can be drawn and the generalizability of the sample
to the broader population of patients with TRD. Finally, the use
of only two doses limits the assessment of the full dose range
and the optimal dosing, and the lowest effective dose remains
to be established (especially doses ,.20 mg/kg, which will be
explored in future studies). However, this proof-of-concept
study is the ﬁrst randomized controlled trial investigating IV
esketamine in the treatment of TRD, and it provides valuable
information for further investigation.atry September 15, 2016; 80:424–431 www.sobp.org/journal 429
Figure 2. (A) Mean plot of Brief Psychiatric Rating Scale (BPRS) total score over time in the double-blind phase by dose. (B) Mean plot of Clinician
Administered Dissociative States Scale (CADSS) total score over time in the double-blind phase by dose. Error bars represent SE. D, day; H, hour; M, minute;
PD, predose.
Esketamine in Adult Treatment-Resistant Depression
Biological
PsychiatryIn conclusion, although the sample size was limited, appro-
ximately 67% of patients with TRD who were treated with
low-dose IV esketamine experienced rapid (within hours),
robust, and persistent improvement of depressive symptoms,
with limited adverse effects. The outcome measures reﬂecting
improvement in depressive symptoms did not differ signiﬁ-
cantly between the two doses of IV esketamine tested here,
suggesting that the lower dose of esketamine may allow for
better tolerability while maintaining efﬁcacy. Additional studies
are required to assess if alternative formulations of esketamine
can be developed to avoid the inconvenience of IV infusion
and how best to develop a treatment paradigm that enables a
sustained long-term response.
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